Last close As at 06/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Healthcare
The last 16.42% of the former Woodford stake in ReNeuron has now been sold to Obotritia Capital. The rest of the former Woodford stake, 16.58%, is now managed by Schroders in an investment trust. Removing the 16.42% overhang should help the shares to stabilise and recover. Clinically, ReNeuron aims to present more retinitis pigmentosa eye data during 2020 adding to the strong initial data. Stroke data from the CTX PISCES III trial are expected around mid-2021. We value ReNeuron at £197m, unchanged.
Written by
ReNeuron Group |
Zero overhang |
Shareholder update |
Pharma & biotech |
10 February 2020 |
Share price performance
Business description
Next events
Analyst
|
||||||||||||||||||||||||||||||||||||||||||||||||||
The last 16.42% of the former Woodford stake in ReNeuron has now been sold to Obotritia Capital. The rest of the former Woodford stake, 16.58%, is now managed by Schroders in an investment trust. Removing the 16.42% overhang should help the shares to stabilise and recover. Clinically, ReNeuron aims to present more retinitis pigmentosa eye data during 2020 adding to the strong initial data. Stroke data from the CTX PISCES III trial are expected around mid-2021. We value ReNeuron at £197m, unchanged.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
03/18 |
0.9 |
(21.0) |
(55.66) |
0.0 |
N/A |
N/A |
03/19 |
2.7 |
(17.2) |
(45.34) |
0.0 |
N/A |
N/A |
03/20e |
6.1 |
(22.8) |
(60.33) |
0.0 |
N/A |
N/A |
03/21e |
3.1 |
(30.8) |
(83.69) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Woodford’s shares now held in Germany
By mid-2019, Woodford Investment Management held 32.99% of ReNeuron split over two funds. On 17 October, 16.42% from one fund was transferred to Link Solutions. The 16.58% in the other fund was transferred on 16 December 2019 to an investment trust managed by Schroder Investment Management. The Link holding has been sold to the private German investment firm Obotritia Capital. Obotritia states (website) that it invests in real estate, venture capital, financial services and other corporate opportunities. The crucial factor is that these shares have ceased to overhang the market.
hRPC cell-based therapy might treat any RP patient
Retinitis pigmentosa (RP) is an inherited, degenerative eye disease caused by one of more than 100 different gene mutations. ReNeuron’s human retinal progenitor cell (hRPC) therapy is cell-based and not mutation specific, so it could potentially treat any RP patient. The dataset for hRPC is currently eight patients, all of whom had at least three months of follow-up (data presented at the 2019 American Academy of Ophthalmology Meeting). The overall result was confounded by two patients who had surgery-related adverse events leading to vision loss. The other six patients had a mean ETDRS visual acuity improvement of 17.8 in the treated eye vs 8.3 in the untreated eye.
Valuation: £197m with cash into 2021
ReNeuron recorded a net loss of £3.9m in H120. Cash and equivalents on 30 September were £21.3m, providing funding into 2021. We retain our indicative value of £197m or 624p per share. This uses a 25% probability of success for hRPC. It is possible that hRPC could become the major valuation contributor as more data emerge over 2020, and its positioning against gene therapy products and path to FDA review become clearer. The CTX stroke indication is a major unmet need, but the current PISCES III trial cannot produce data before mid-2021, our expected launch window as from 2024 onwards is unchanged .
Exhibit 1: Financial summary
£'000s |
2018 |
2019 |
2020e |
2021e |
||
Year end 31 March |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
||||||
Revenue |
|
|
897 |
2,720 |
6,094 |
3,094 |
Cost of Sales |
0 |
0 |
0 |
0 |
||
Gross Profit |
897 |
2,720 |
6,094 |
3,094 |
||
R&D expenses |
(16,657) |
(16,240) |
(24,685) |
(28,634) |
||
SG&A expenses |
(4,616) |
(4,779) |
(5,078) |
(5,586) |
||
EBITDA |
|
|
(20,222) |
(17,915) |
(23,448) |
(30,965) |
Operating Profit (before amort. and except.) |
|
(20,376) |
(18,299) |
(23,575) |
(31,032) |
|
Intangible Amortisation |
0 |
0 |
0 |
0 |
||
Exceptionals |
0 |
0 |
0 |
0 |
||
Operating Profit |
(20,376) |
(18,299) |
(23,575) |
(31,032) |
||
Other |
0 |
0 |
0 |
0 |
||
Net Interest |
(591) |
1,064 |
792 |
240 |
||
Profit Before Tax (norm) |
|
|
(20,967) |
(17,235) |
(22,783) |
(30,792) |
Profit Before Tax (FRS 3) |
|
|
(20,967) |
(17,235) |
(22,783) |
(30,792) |
Tax |
3,352 |
2,887 |
3,579 |
4,152 |
||
Profit After Tax (norm) |
(17,615) |
(14,348) |
(19,204) |
(26,640) |
||
Profit After Tax (FRS 3) |
(17,615) |
(14,348) |
(19,204) |
(26,640) |
||
Average Number of Shares Outstanding (m) |
31.6 |
31.6 |
31.8 |
31.8 |
||
EPS - normalised (p) |
|
|
(55.66) |
(45.34) |
(60.33) |
(83.69) |
EPS - FRS 3 (p) |
|
|
(55.66) |
(45.34) |
(60.33) |
(83.69) |
Dividend per share (p) |
0.0 |
0.0 |
0.0 |
0.0 |
||
BALANCE SHEET |
||||||
Fixed Assets |
|
|
912 |
1,522 |
1,682 |
1,959 |
Intangible Assets |
186 |
186 |
186 |
186 |
||
Tangible Assets |
726 |
632 |
792 |
1,069 |
||
Other |
0 |
704 |
704 |
704 |
||
Current Assets |
|
|
41,706 |
29,988 |
11,684 |
15,849 |
Stocks |
0 |
0 |
0 |
0 |
||
Debtors |
1,285 |
834 |
834 |
834 |
||
Cash and deposits |
37,411 |
26,386 |
8,082 |
12,247 |
||
Other |
3,010 |
2,768 |
2,768 |
2,768 |
||
Current Liabilities |
|
|
(5,949) |
(7,402) |
(7,402) |
(7,402) |
Creditors |
(5,949) |
(7,261) |
(7,261) |
(7,261) |
||
Short term borrowings |
0 |
0 |
0 |
0 |
||
Short term leases |
0 |
(141) |
(141) |
(141) |
||
Other |
0 |
0 |
0 |
0 |
||
Long Term Liabilities |
|
|
0 |
(864) |
(864) |
(30,864) |
Long term borrowings |
0 |
0 |
0 |
(30,000) |
||
Long term leases |
0 |
0 |
0 |
0 |
||
Other long term liabilities |
0 |
0 |
0 |
0 |
||
Net Assets |
|
|
36,669 |
24,108 |
5,965 |
(19,593) |
CASH FLOW |
||||||
Operating Cash Flow |
|
|
(14,887) |
(11,947) |
(18,808) |
(25,733) |
Net Interest |
383 |
342 |
792 |
242 |
||
Tax |
0 |
0 |
0 |
0 |
||
Capex |
(235) |
(239) |
(287) |
(344) |
||
Acquisitions/disposals |
0 |
0 |
0 |
0 |
||
Financing |
0 |
0 |
0 |
0 |
||
Dividends |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
||
Net Cash Flow |
(14,739) |
(11,844) |
(18,304) |
(25,835) |
||
Opening net debt/(cash) |
|
|
(53,061) |
(37,411) |
(26,380) |
(8,076) |
HP finance leases initiated |
0 |
0 |
0 |
0 |
||
Other |
(911) |
813 |
0 |
0 |
||
Closing net debt/(cash) |
|
|
(37,411) |
(26,380) |
(8,076) |
17,759 |
Source: ReNeuron accounts, Edison Investment Research
|
|
Research: Investment Companies
Utilico Emerging Markets Trust (UEM) is managed by Charles Jillings at ICM Group. It is a specialist fund focusing on infrastructure and utility assets in emerging markets. The manager is encouraged by the prospects for UEM’s investee companies, supported by urbanisation and significant growth in the regions’ middle classes. He also suggests that it ‘is a very interesting time in the world’, with issues such as climate change and the shift to renewable energy high up on the global agenda, which should be beneficial for UEM’s investments. While not used as a formal benchmark, as shown in the chart below, the trust’s NAV has markedly outperformed the MSCI Emerging Markets Index over the last decade.